SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001867096-23-000136
Filing Date
2023-11-09
Accepted
2023-11-09 07:20:00
Documents
15
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xers-20231109.htm   iXBRL 8-K 29506
2 EX-99.1 exh991q32023earningsrelease.htm EX-99.1 116336
7 picture1reviseda.jpg GRAPHIC 4446
  Complete submission text file 0001867096-23-000136.txt   336701

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20231109.xsd EX-101.SCH 2155
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20231109_def.xml EX-101.DEF 17341
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20231109_lab.xml EX-101.LAB 32808
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20231109_pre.xml EX-101.PRE 17736
9 EXTRACTED XBRL INSTANCE DOCUMENT xers-20231109_htm.xml XML 2930
Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

IRS No.: 871082097 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40880 | Film No.: 231390051
SIC: 2834 Pharmaceutical Preparations